Skip to main content
Contact us

FDF CDMO
Finished Dosage Forms Contract Manufacturing Services

Your Trusted Partners for FDF Contract Manufacturing and Development

Showing 114 facilities
HIPRA BIOTECH SERVICES | Amer
Spain

HIPRA BIOTECH SERVICES | Amer

HIPRA Biotech Services

End-to-end internal capabilities from cell line development to commercial manufacturing.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia)

COMPLIANCE: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

BSL (Biological Safety Level): 1, 2

USE: Human, Veterinary

BATCH SIZE: Large, Small, Medium

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, BIOLOGICS

REGION: Europe

JAFRAL
Slovenia

JAFRAL

JAFRAL

Integrated biotechnology facility providing R&D, non-GMP and GMP manufacturing, QC testing, and fill & finish services for advanced biologics.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

COMPLIANCE: ICH, FDA (cGMP), ISO, EMA (EU GMP), World Health Organization (GMP / HACCP), SQF (Safe Quality Food)

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), SFDA (Saudi Arabia), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia)

BSL (Biological Safety Level): 1, 2

CATEGORY / PRODUCT: COSMETICS, NUTRACEUTICALS, FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS

USE: Human, Veterinary

BATCH SIZE: Large, Small, Medium

CONTROLLED SUBSTANCES: Lowest potential for abuse

THERAPEUTIC AREAS OF EXPERTISE (ATC): (J) Antiinfectives for systemic use, (D) Dermatologicals, (V06) Nutrients, (R) Respiratory system, (A) Digestive tract and metabolism

REGION: Europe

Bilthoven Biologicals Drug Substance and Drug Product Facilities
Netherlands

Bilthoven Biologicals Drug Substance and Drug Product Facilities

Bilthoven Biologicals BV

Multi-product GMP facilities for Drug Substance and Drug Product.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), MHRA (UK)

BSL (Biological Safety Level): 1, 2

USE: Human

BATCH SIZE: Large, Small, Medium

COMPLIANCE: EMA (EU GMP)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS

REGION: Europe

HBM Pharma
Slovakia

HBM Pharma

Hbm Pharma

EU-GMP-certified CMO based in Martin, Slovakia. The company provides manufacturing and packaging servicesfor sterile pharm. products and solid oral dosage forms

MARKETS: EMA (EU), NMPA (China), Health Canada (Canada), ANVISA (Brazil), COFEPRIS (Mexico), Russian Health Authorities, MHRA (UK), SFDA (Saudi Arabia), Turkish Health Authorities, TGA (Australia)

COMPLIANCE: ISO, Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), UAE Ministry of Health & Prevention, NMPA (China GMP), EMA (EU GMP), Health Canada (Canada GMP), ANVISA (Brazil)

USE: Human

BATCH SIZE: Large, Small, Medium

SERVICES: Analytical / QC services, Packaging, Quality Assurance services, Manufacturing services

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

CONTROLLED SUBSTANCES: High potential for abuse & medical use

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, SERVICES

REGION: Europe

Laboratorio REIG JOFRE, SA (TOLEDO PLANT)
Spain

Laboratorio REIG JOFRE, SA (TOLEDO PLANT)

LABORATORIO REIG JOFRE SA

Betalactam antibiotics (FDF) development and manufacturing state-of-the-art facilities.

MARKETS: EMA (EU), ANVISA (Brazil), ISP (Chile), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), INVIMA (Colombia), SFDA (Saudi Arabia), TGA (Australia)

REGION: APAC, MENA, LATAM, Europe, North America

COMPLIANCE: DIGEMID, ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

BATCH SIZE: Large, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (J) Antiinfectives for systemic use

CONTROLLED SUBSTANCES: Lowest potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Laboratorios Grifols | Barcelona Plant
Spain

Laboratorios Grifols | Barcelona Plant

Grifols International

Sterile manufacturing solutions (small molecules) in flexible bags and vials.

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), ANMAT (Argentina), MFDS (South Korea), TGA (Australia)

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (M) Musculoskeletal system, (N) Nervous system, (A) Digestive tract and metabolism

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

White Raven - Legiapark
Belgium

White Raven - Legiapark

White Raven

Fill and finish site dedicated to GMP Formulation and the Aseptic filling of Sterile Liquid Injectables.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU)

REGION: Europe

USE: Human

BSL (Biological Safety Level): 1, 2

SERVICES: Manufacturing services, Packaging

BATCH SIZE: Small, Medium

COMPLIANCE: EMA (EU GMP)

CATEGORY / PRODUCT: BIOLOGICS, FDF / DRUG PRODUCTS

Laboratorio REIG JOFRE, SA (BARCELONA PLANT)
Spain

Laboratorio REIG JOFRE, SA (BARCELONA PLANT)

LABORATORIO REIG JOFRE SA

Injectable (lyo and liquid) and Liquid manufacturing facilities.

BSL (Biological Safety Level): 3, 1, 2

MARKETS: EMA (EU), PMDA (Japan), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MHRA (UK), INVIMA (Colombia), MFDS (South Korea), TGA (Australia)

REGION: Europe

BATCH SIZE: Large, Medium

USE: Human, Veterinary

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (N) Nervous system, (R) Respiratory system, (A) Digestive tract and metabolism

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

COMPLIANCE: PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), ECOVADIS, INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

BAG Health Care
Germany

BAG Health Care

BAG Health Care GmbH

Parenteral F&F provider for vials in small to mid sized batches.

MARKETS: EMA (EU), MHRA (UK), TGA (Australia)

REGION: Europe

USE: Human, Veterinary

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

BATCH SIZE: Small, Medium

COMPLIANCE: EMA (EU GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Lifecore Injectables CDMO
United States

Lifecore Injectables CDMO

Lifecore Biomedical

CDMO that manufactures clinical & commercial sterile injectable drug products.

BSL (Biological Safety Level): 3, 1, 2

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CONTROLLED SUBSTANCES: Lowest potential for abuse

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

REGION: North America

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Laboratorios Grifols | Murcia Plant
Spain

Laboratorios Grifols | Murcia Plant

Grifols International

Sterile manufacturing solutions (small molecules) in flexible bags.

MARKETS: EMA (EU), FDA (USA), ANVISA (Brazil), ANMAT (Argentina), MFDS (South Korea), TGA (Australia)

SERVICES: Logistics, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging

REGION: Europe

COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (N) Nervous system, (A) Digestive tract and metabolism

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

EVER Pharma Jena GmbH
Germany

EVER Pharma Jena GmbH

EVER Neuro Pharma GmbH

Specialized CDMO for development and production of small molecules injectables.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human

BSL (Biological Safety Level): 1, 2

THERAPEUTIC AREAS OF EXPERTISE (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins, (L) Antineoplastic and immunomodulating agents, (N) Nervous system

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+54 more facilities

Create free account

Developing a finished dosage form (FDF) from an innovative molecule is a journey filled with complexity, precision, and the need for specialized expertise. Identifying the ideal partner for finished forms production is crucial to navigate this process successfully. Finding the right FDF CDMO (Finished Dosage Form Contract Development and Manufacturing Organization) can make all the difference in delivering safe, effective, and patient-ready solutions. Top-tier finished dosage form manufacturing partners combine scientific knowledge with operational excellence to transform molecules into therapies that improve lives. Whether you need assistance with formulation, manufacturing, or regulatory support, expert FDF CDMOs provide the essential services to ensure your molecule’s success.

What Are Finished Dosage Forms (FDF)?

Finished dosage forms refer to the final product a patient or consumer uses, such as tablets, capsules, syrups, or injectable solutions. These drug products represent the culmination of pharmaceutical development, where active ingredients become usable medicines through specialized finished forms contract manufacturing processes. These forms must meet stringent quality, safety, and efficacy standards to ensure proper delivery and therapeutic outcomes. Depending on the therapeutic area and user preferences, different FDF types are selected to optimize results.

Types of Finished Dosage Forms and Applications

Leading finished form CDMOs offer extensive experience across a variety of dosage forms, catering to the specific needs of pharmaceutical and biotechnological drug products:

Oral Solid Dosage Forms: Tablets, capsules, and specialty oral solids like modified-release formulations for enhanced bioavailability and controlled drug delivery.

Oral Liquid and Semisolid Forms: Syrups, suspensions, emulsions, and gels for pediatric, geriatric, or topical applications, addressing stability and palatability challenges.

Sterile Dosage Forms: Injectables (IV, IM, SC, intradermal), sterile ophthalmic, nasal, and topical products, and implants for sustained release—all requiring specialized facilities and stringent quality controls.

Inhalation Products: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and nebulizers delivering medication directly to the lungs with precise dosing mechanisms.

Essential Services Offered by FDF CDMOs

An expert finished forms CDMO provides a comprehensive suite of services to ensure your FDF meets market demands and regulatory standards:

Developing scalable formulation prototypes through Formulation Development: Optimizing API stability and physical properties.

Selecting the optimal delivery matrix via Dosage Form Selection: Tailored to target patient demographics and release profiles.

Producing early-stage clinical trial supplies with Clinical Trial Manufacturing: Supporting Phase I-III requirements under cGMP.

Scaling up output seamlessly through Commercial Manufacturing: Ensuring commercial-volume batch reproducibility.

Customizing secondary containment via Packaging and Labeling: Blister packaging, bottling, serialization, and cold-chain support.

Navigating global agency filings with Regulatory Support: Assisting IND, NDA, ANDA, and DMF submissions.

Maintaining stringent batch compliance via Quality Assurance: End-to-end testing, validation, and batch release capabilities.

Why Partner with a Specialized FDF CDMO?

Choosing the right FDF CDMO offers multiple advantages including:

Leveraging specialized formulation science with Deep Expertise in FDF Development: Solving complex delivery challenges.

Transitioning smoothly across batch volumes via Scalability: From lab-scale trial batches to full commercial output.

Streamlining development pathways through Accelerated Time to Market: Utilizing established site infrastructure and process knowledge.

Eliminating heavy capital infrastructure expenditure with Cost Efficiency: Accessing specialized manufacturing suites on demand.

Mitigating approval hazards through Regulatory Compliance: Operating within FDA, EMA, and global cGMP guidelines.

Addressing Challenges in FDF Manufacturing

FDF production involves unique challenges, such as maintaining sterility, palatability, controlled release, and consistency across all administration routes. Partnering with an experienced FDF CDMO helps overcome these hurdles effectively.

Top Finished Dosage Forms Manufacturers and Their FDF CDMO Services

Lannett: Oral Solid Dose (OSD) and Liquids. [See CDMO profile]

Pharmaloop (a Salvat company): Fully integrated drug product CDMO solutions. [See CDMO profile]

Reig Jofre: FDF development and manufacturing state-of-the-art facilities. [See CDMO profile]

Cenexi: Injectables manufacturing. [See CDMO profile]

Grifols International: Injectables manufacturing CDMO. [See CDMO profile]

Liof Pharma: Aseptic manufacturing and lyophilization of biologics and injectable drugs. [See CDMO profile]

CDM Lavoisier: Glass ampoules, vials, and plastic (BFS) ampoules. [See CDMO profile]

FAES FARMA: Developer and manufacturer of human medicinal products. [See CDMO profile]

VIVUNT PHARMA: CDMO for sterile oncology drugs. [See CDMO profile]

ASCIL Biopharm: GMP R&D and clinical batch pilot plant. [See CDMO profile]

Cambrex: Early development of small molecule products. [See CDMO profile]

HIPRA BIOTECH SERVICES: End-to-end capabilities from cell line development to commercial manufacturing. [See CDMO profile]

Skyepharma: Integrated FDF CDMO for oral technologies. [See CDMO profile]

Ophtapharm, a Sentiss company: Ophthalmic and otic products. [See CDMO profile]

HISTOCELL S.L.: Cell therapies, medical devices, dermocosmetics. [See CDMO profile]

Sichuan Huiyu Pharmaceuticals Co., Ltd: Complex and high-value dosage forms. [See CDMO profile]

i+Med | Drug products: Controlled release drug products. [See CDMO profile]

Aenova Group: Manufacturing, development, and technology services. [See CDMO profile]

CARBOGEN AMCIS: GMP sterile liquid and lyophilized drug products. [See CDMO profile]

Adragos Pharma: Value Added Medicines and HPAPI capabilities. [See CDMO profile]

AdhexPharma SAS: Transdermal patches and oromucosal films. [See CDMO profile]

Lukas Heil-Betriebsstätte: GMP sterile and aseptic liquids production. [See CDMO profile]

Adare Pharma: Oral dosage forms for Pharma, Animal Health, OTC. [See CDMO profile]

Basic Pharma Manufacturing: Injectables, sterile forms manufacturing. [See CDMO profile]

CZ Vaccines: Clinical trials facility. [See CDMO profile]

BAG Health Care: Parenteral F&F for vials. [See CDMO profile]

SINOWAY INDUSTRIAL CO., LTD: API and key intermediates. [See CDMO profile]

Unither Pharmaceuticals: Affordable healthcare solutions. [See CDMO profile]

APR LAB: Rare and ultra-rare disease products. [See CDMO profile]

Sidefarma: Small and medium batch manufacturing. [See CDMO profile]

Glatt Pharmaceutical Services: End-to-end complex dosage forms. [See CDMO profile]

SWISS PARENTERALS: Diverse sterile products production. [See CDMO profile]

Darnytsia Kyiv: Combining advanced facilities, stringent quality control, and expert staff to deliver reliable, compliant, and innovative solutions for its clients. [See CDMO profile]

Cellex Cell Professionals: CGT CDMO Cell Manufacturing Plant and Collection Center for Starting Materials. [See CDMO profile]

Content Group: Tubilux Pharma: registered office; manufacturing facility. [See CDMO profile]

Ascendia Pharmaceutical Solutions: GMP-certified CDMO for sterile and non-sterile manufacturing, formulation development, and analytical testing. [See CDMO profile]

White Raven: Fill & finish site dedicated to GMP formulation and aseptic filling of sterile liquid injectables. [See CDMO profile]

Lifecore Injectables CDMO: Clinical and commercial manufacturing of sterile injectable drug products. [See CDMO profile]

Related Content

Leading Injectables CDMO Companies | Injectables Contract Manufacturing Services

Leading Steriles CDMO Companies | Steriles Contract Manufacturing Services

Leading OSD CDMO Companies | Oral Solids Contract Manufacturing Services

Leading Oral Liquids CDMO Companies | Oral Liquid Formulations Contract Manufacturing Services

Leading Topical CDMO Companies | Transdermal Contract Manufacturing Services

Partner with the Right FDF CDMO for Your Needs

Collaborating with a top-tier CDMO ensures your molecule’s journey from concept to commercial product is seamless. At MAI CDMO Network, we connect you with pre-vetted finished forms CDMO experts who specialize in transforming innovative molecules into ready-to-use finished dosage forms. With our network, you gain access to world-class facilities, cutting-edge technologies, and unmatched expertise to bring your product to market successfully.

Ready to take your molecule to the next level? Explore our network of trusted CDMO partners and find the ideal solution for your drug product manufacturing needs.